Oxford's Hill says its vaccine won't be available in U.S. until mid-2021 if FDA waits for trial end

Dec 9 (Reuters) - Jenner Institute Director Adrian Hill, who
oversees the Oxford-AstraZeneca COVID-19 vaccine
research and development, told NBC News that if the U.S. Food
and Drug Administration waits for the end of their vaccine
trial, the vaccine would not be available in the U.S. until "the
middle of next year."

"That's too late to take the value of this vaccine, which is
effective, available at large scale and easily deployed," he
said in remarks tweeted by NBC News https://bit.ly/3n4UYS6 on
Wednesday.

(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie
Adler)